Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Clonidine HCl Mucoadhesive

Small molecule · developed by Monopar Therapeutics

Phase 2/3 Most advanced trial (none active)

MNPR Developer

1 Registered trials

What is Clonidine HCl Mucoadhesive?

Clonidine HCl Mucoadhesive is a buccal tablet formulation containing 100 μg of clonidine per tablet, studied for the treatment of chemoradiotherapy-induced severe oral mucositis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Oncology
Developer: Monopar Therapeutics (MNPR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04648020	Phase 2/3	Chemoradiotherapy-Induced Severe Oral Mucositis	Terminated	MNPR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chemoradiotherapy-Induced Severe Oral Mucositis

More from Monopar Therapeutics

Camsirubicin Phase 1 MNPR-101-DFO*-89Zr Phase 1 MNPR-101-PCTA-177Lu Phase 1

Sources

ClinicalTrials.gov NCT04648020

Updated Oct 3, 2026. Something wrong or missing? Report it on the MNPR page.

Follow MNPR, the company behind Clonidine HCl Mucoadhesive

See MNPR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MNPR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z